α-Adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with α-adrenoceptor antagonists Karl-Erik Andersson Topic Paper 01 April 2002 Pages: 390 - 396
Tamsulosin: an overview Christopher ChappleKarl-Erik Andersson Topic Paper 01 April 2002 Pages: 397 - 404
Alfuzosin: a clinically uroselective α1-blocker Klaus HöfnerUdo Jonas Topic Paper 01 April 2002 Pages: 405 - 412
Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia G. BartschR. RittmasterH. Klocker Topic Paper 01 April 2002 Pages: 413 - 425
The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia Kurt Dreikorn Topic Paper 01 April 2002 Pages: 426 - 435
Future drugs for the treatment of benign prostatic hyperplasia Karl-Erik AnderssonC. R. ChappleK. Höfner Topic Paper 01 April 2002 Pages: 436 - 442
Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men Matthias OelkeKlaus HöfnerUdo Jonas Topic Paper 01 April 2002 Pages: 443 - 452
The influence of obstructive interval on patency rates following microsurgical epididymovasostomy Richard A. SchoorSamir M. ElhanblyCraig S. Niederberger Free Paper 01 April 2002 Pages: 453 - 456
In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cell accumulation and glandular epithelium trophism in the rat prostate Dionisios MitropoulosAspasia KyroudiPanagiotis Karayannacos Free Paper 01 April 2002 Pages: 457 - 461
Erratum to: Systemic and cavernous plasma levels of endothelin (1–21) during different penile conditions in healthy males and patients with erectile dysfunction Armin J. BeckerStefan ÜckertUdo Jonas Erratum 01 April 2002 Pages: 462 - 462